Evolution Research Group (ERG) a leading independent research site company specializing in a number of therapeutic areas including Psychiatry, Neurology, CNS, NASH, Diabetes and others announces a strategic partnership with Invicro LLC, a Konica Minolta Company, to offer biotech and pharma sponsors early to late phase clinical research trials, advanced data analysis and project management services.
Invicro, a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for clinical research. The two hope that this partnership will offer pharmaceutical sponsors a seamless process for inpatient and outpatient clinical research trials backed by unparalleled support including centralized recruiting, operational excellence, clinical consulting, advanced data analysis and project management support.
The Partnership Synergies: An Investigative Site & Tech Services Provider
With over 5,000 completed clinical trials leveraging a broad network of state-of-the-art ERG portfolio and affiliate sites throughout the United States, supporting both early and late-phase clinical trials. While Invicro has processed nearly 25-million (DICOM) images and defined over 6-million unique quantification data points. The combined strength of ERG and Invicro will offer pharma and biotech customers to uncover answers to support more timely and accurate decision-making throughout their clinical research trials.
About Evolution Research Group
ERG is one of the largest, independent, wholly owned research site organizations in the country, with a leading position in the CNS clinical trials industry. Evolution Research Group, LLC comprises 13 wholly owned and operated clinical research units, and an established network of affiliated clinical research sites. ERG conducts a wide range of simple and highly complex trials in specialized populations, including those suffering from psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency, hepatic impairment, as well as normal healthy volunteers.
The ERG team, which consists of over 400 employees, owns and operates specialty inpatient and outpatient research units across the country, conducting phase I-IV clinical research trials. Additionally, ERG manages a network of affiliated clinical research sites and has access to over 32 million potential patients to support sponsors conducting research.
Headquartered in Boston, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®.
As part of the Konica Minolta precision medicine organization and with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. For more information, visit their website.
Call to Action: Interested in following this partnership? TrialSite News will be tracking—sign up for the Daily Digest to receive updates.Source: BusinessWire